AAAAAA
Results:
1-7
|
Results: 7
Authors:
Logothetis, CJ
Wu, KK
Finn, LD
Daliani, D
Figg, W
Ghaddar, H
Gutterman, JU
Citation: Cj. Logothetis et al., Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer, CLIN CANC R, 7(5), 2001, pp. 1198-1203
Authors:
Tu, SM
Millikan, RE
Mengistu, B
Delpassand, ES
Amato, RJ
Pagliaro, LC
Daliani, D
Papandreou, CN
Smith, TL
Kim, J
Podoloff, DA
Logothetis, CJ
Citation: Sm. Tu et al., Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial, LANCET, 357(9253), 2001, pp. 336-341
Authors:
Amato, RJ
Millikan, R
Daliani, D
Wood, L
Logothetis, C
Pollack, A
Citation: Rj. Amato et al., Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma, CLIN CANC R, 6(1), 2000, pp. 72-77
Authors:
Daliani, D
Citation: D. Daliani, Development of angiogenesis inhibition as therapy for prostate cancer, ONCOLOGY-NY, 14(12), 2000, pp. 21-23
Authors:
Pagliaro, L
Daliani, D
Amato, R
Tu, SM
Jones, D
Smith, T
Logothetis, C
Millikan, R
Citation: L. Pagliaro et al., A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma, CANCER, 89(3), 2000, pp. 615-618
Authors:
Bubley, GJ
Carducci, M
Dahut, W
Dawson, N
Daliani, D
Eisenberger, M
Figg, WD
Freidlin, B
Halabi, S
Hudes, G
Hussain, M
Kaplan, R
Myers, C
Oh, W
Petrylak, DP
Reed, E
Roth, B
Sartor, O
Scher, H
Simons, J
Sinibaldi, V
Small, EJ
Smith, MR
Trump, DL
Vollmer, R
Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Authors:
Daliani, D
Papandreou, CN
Citation: D. Daliani et Cn. Papandreou, Markers of androgen-independent progression of prostatic carcinoma, SEMIN ONCOL, 26(4), 1999, pp. 399-406
Risultati:
1-7
|